AVR engaged the FDA to progress the IDE for the PARADIGM Trial, with Michael J. Reardon confirmed as Co-Chair.

The entities involved

• AVR →

  Belgian company

  • AVR presented results at a conference in San Diego and confirmed it conducts clinical trials in the US and Australia.Sun 20:58
• FDA →
  • UK and US regulatory bodies are setting submission targets and offering R&D rebate programs to companies.19:08
  • The FDA suspended licenses of outlets linked to Zepto and Domino's following a statewide order in Maharashtra.18:18

Related events

• FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.Oct 28
• enVVeno Medical received IDE approval from the FDA for its pivotal study on July 31, 2026.Jul 31
• An AI-designed drug is currently in trials, prompting a focus on global legal and ethical standards.Jun 30
• EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.Jun 8
• Vance Thompson Vision advocated for standard product approval during an FDA committee meeting chaired by Michael X. Repka.Sat 01:54